Skip to content

Intra-Cellular Therapies, Inc.: 10-Q filed 2021-05-10

What Intra-Cellular Therapies, Inc. reported in its quarterly report filed 2021-05-10 (fiscal Q1 2021): 40 published measures, 84 facts as tagged in accession 0001193125-21-155623.

This filing

Form
10-Q (quarterly report)
Filed
2021-05-10
Fiscal period
fiscal Q1 2021
Accession
0001193125-21-155623 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Intra-Cellular Therapies, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-03-31674,488,568USD
At 2020-12-31717,313,674USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-03-3162,338,810USD
At 2020-12-3160,453,570USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-03-31612,149,758USD
At 2020-12-31656,860,104USD
At 2020-03-31430,448,330USD
At 2019-12-31195,007,271USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-03-31129,979,888USD
At 2020-12-3160,045,933USD
At 2020-03-31179,593,032USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-52,739,943USD90
2020-01-01 to 2020-03-31-47,410,602USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-47,766,952USD90
2020-01-01 to 2020-03-31-51,226,218USD91

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2021-01-01 to 2021-03-310USD90
2020-01-01 to 2020-03-3122,049USD91

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2021-01-01 to 2021-03-3115,878,329USD90
2020-01-01 to 2020-03-311,083,479USD91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-03-311,431,658USD90
2020-01-01 to 2020-03-31277,567,347USD91

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-03-31116,269,249USD90
2020-01-01 to 2020-03-31-152,984,946USD91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-03-31-989,843,975USD
At 2020-12-31-937,104,032USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-01-01 to 2021-03-315,000USD90
2020-01-01 to 2020-03-313,281USD91

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-03-311,871,338USD
At 2020-12-311,998,346USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-03-316,778,436USD90
2020-01-01 to 2020-03-315,504,297USD91

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-53,218,693USD90
2020-01-01 to 2020-03-31-49,085,524USD91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-03-31649,100,443USD
At 2020-12-31690,904,482USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-03-3139,701,710USD
At 2020-12-3136,853,223USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-03-318,720,957USD
At 2020-12-315,501,825USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2021-03-3113,661,992USD
At 2020-12-3110,764,583USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-01-01 to 2021-03-3169,097,022USD90
2020-01-01 to 2020-03-3150,169,003USD91

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2021-03-317,579,393USD
At 2020-12-317,056,385USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-01-01 to 2021-03-3115,058,168USD90
2020-01-01 to 2020-03-3116,003,326USD91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-03-3181,133,849shares
At 2020-12-3180,463,089shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2021-03-31131,379,888USD
At 2020-12-3161,445,933USD
At 2020-03-31180,993,032USD
At 2019-12-31107,636,849USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2021-03-31246,545USD
At 2020-12-31480,584USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-03-3123,430,703USD
At 2020-12-3124,324,762USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2021-03-3128,200,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2021-03-316,034,895USD
At 2020-12-316,034,895USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-03-314,163,557USD
At 2020-12-314,036,549USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2021-03-3186,084USD
At 2020-12-3186,084USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2021-03-3114,494,384USD
At 2020-12-3114,235,455USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-52,734,943USD90
2020-01-01 to 2020-03-31-47,407,321USD91

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-52,739,943USD90
2020-01-01 to 2020-03-31-47,410,602USD91

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-52,973,982USD90
2020-01-01 to 2020-03-31-47,684,118USD91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-03-3152,583,639USD90
2020-01-01 to 2020-03-3134,096,366USD91

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-01-01 to 2021-03-31127,008USD90
2020-01-01 to 2020-03-31148,802USD91

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2020-01-01 to 2020-12-3117,900,000USD366
2020-01-01 to 2020-03-31276,978,186USD91

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-03-312,897,409USD90
2020-01-01 to 2020-03-311,351,013USD91

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-03-31523,008USD90
2020-01-01 to 2020-03-311,391,124USD91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-03-313,219,132USD90
2020-01-01 to 2020-03-313,569,058USD91

Inspect the source

Entity
Intra-Cellular Therapies, Inc. / CIK 0001567514
Captured
2026-09-21T17:20:04.465Z
SEC response SHA-256
d515a2828c30b442b80d2f88dbecd3b8d47803a78a686cc6f7c16f5ab9f2019e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001567514.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))